Bio-Thera Solutions, Ltd. (SHA:688177)

China · Delayed Price · Currency is CNY

17.11

+0.03 (0.18%)

At close: Jul 31, 2026

Bio-Thera Solutions Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	980.25	935.22	743.17	704.79	455.13	836.58
Revenue Growth	24.38%	25.84%	5.44%	54.85%	-45.60%	357.49%
Gross Profit	783.42	737.8	513.46	510.13	264.04	800.68
Operating Income	-465.2	-407.95	-539.04	-464.91	-529.22	38.75
Net Income	-390.44	-331.94	-510.3	-394.53	-480.4	81.94
Earnings Per Share	-0.94	-0.80	-1.23	-0.95	-1.16	0.20
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
China	878.06
Overseas	57.16
Total	935.22

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	247.8	218.61	380.02	495.01	795.83	1,450
Total Debt	781.37	686.04	628.58	482.62	9.51	32.43
Net Cash (Debt)	-533.57	-467.43	-248.56	12.39	786.33	1,418
Net Cash Growth	-	-	-	-98.42%	-44.54%	14.41%
Net Cash Per Share	-1.28	-1.13	-0.60	0.03	1.90	3.46

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-115.94	-82.11	-55.65	-460.87	-412.82	236.27
Capital Expenditures	-195.89	-121.74	-126.85	-262.14	-258.82	-77.89
Free Cash Flow	-311.83	-203.86	-182.5	-723.01	-671.64	158.38
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	79.92%	78.89%	69.09%	72.38%	58.01%	95.71%
Operating Margin	-47.46%	-43.62%	-72.53%	-65.96%	-116.28%	4.63%
Pretax Margin	-39.80%	-35.46%	-68.67%	-55.96%	-105.55%	10.88%
Profit Margin	-39.83%	-35.49%	-68.67%	-55.98%	-105.55%	9.79%
FCF Margin	-31.81%	-21.80%	-24.56%	-102.58%	-147.57%	18.93%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 2, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	-	-	-	130.54
Forward PE	-	24.42	19.58	-	-	-
P/FCF Ratio	-	-	-	-	-	67.53
PS Ratio	7.23	10.25	10.80	24.23	19.82	12.79